BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7912725)

  • 1. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
    Tomiak E; Piccart MJ; Kerger J; Lips S; Awada A; de Valeriola D; Ravoet C; Lossignol D; Sculier JP; Auzannet V
    J Clin Oncol; 1994 Jul; 12(7):1458-67. PubMed ID: 7912725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
    Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
    J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of Taxotere: five-day schedule.
    Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
    J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
    Extra JM; Rousseau F; Bruno R; Clavel M; Le Bail N; Marty M
    Cancer Res; 1993 Mar; 53(5):1037-42. PubMed ID: 8094996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a place for "dose-dense" weekly schedules of the taxoids?
    Löffler TM
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):32-4. PubMed ID: 9865710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
    Bissett D; Setanoians A; Cassidy J; Graham MA; Chadwick GA; Wilson P; Auzannet V; Le Bail N; Kaye SB; Kerr DJ
    Cancer Res; 1993 Feb; 53(3):523-7. PubMed ID: 8093854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel (Taxotere) administered in weekly schedules.
    Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
    J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly administration of docetaxel (Taxotere): summary of clinical data.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of docetaxel with concomitant thoracic radiation therapy.
    Mauer AM; Masters GA; Haraf DJ; Hoffman PC; Watson SM; Golomb HM; Vokes EE
    J Clin Oncol; 1998 Jan; 16(1):159-64. PubMed ID: 9440738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly schedules of docetaxel.
    Burris H
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.